Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline

May N Tsao, Dirk Rades, Andrew Wirth, Simon S Lo, Brita L Danielson, Laurie E Gaspar, Paul W Sperduto, Michael A Vogelbaum, Jeffrey D Radawski, Jian Z Wang, Michael T Gillin, Najeeb Mohideen, Carol A Hahn, Eric L Chang, May N Tsao, Dirk Rades, Andrew Wirth, Simon S Lo, Brita L Danielson, Laurie E Gaspar, Paul W Sperduto, Michael A Vogelbaum, Jeffrey D Radawski, Jian Z Wang, Michael T Gillin, Najeeb Mohideen, Carol A Hahn, Eric L Chang

Abstract

Purpose: To systematically review the evidence for the radiotherapeutic and surgical management of patients newly diagnosed with intraparenchymal brain metastases.

Methods and materials: Key clinical questions to be addressed in this evidence-based Guideline were identified. Fully published randomized controlled trials dealing with the management of newly diagnosed intraparenchymal brain metastases were searched systematically and reviewed. The U.S. Preventative Services Task Force levels of evidence were used to classify various options of management.

Results: The choice of management in patients with newly diagnosed single or multiple brain metastases depends on estimated prognosis and the aims of treatment (survival, local treated lesion control, distant brain control, neurocognitive preservation). Single brain metastasis and good prognosis (expected survival 3 months or more): For a single brain metastasis larger than 3 to 4 cm and amenable to safe complete resection, whole brain radiotherapy (WBRT) and surgery (level 1) should be considered. Another alternative is surgery and radiosurgery/radiation boost to the resection cavity (level 3). For single metastasis less than 3 to 4 cm, radiosurgery alone or WBRT and radiosurgery or WBRT and surgery (all based on level 1 evidence) should be considered. Another alternative is surgery and radiosurgery or radiation boost to the resection cavity (level 3). For single brain metastasis (less than 3 to 4 cm) that is not resectable or incompletely resected, WBRT and radiosurgery, or radiosurgery alone should be considered (level 1). For nonresectable single brain metastasis (larger than 3 to 4 cm), WBRT should be considered (level 3). Multiple brain metastases and good prognosis (expected survival 3 months or more): For selected patients with multiple brain metastases (all less than 3 to 4 cm), radiosurgery alone, WBRT and radiosurgery, or WBRT alone should be considered, based on level 1 evidence. Safe resection of a brain metastasis or metastases causing significant mass effect and postoperative WBRT may also be considered (level 3). Patients with poor prognosis (expected survival less than 3 months): Patients with either single or multiple brain metastases with poor prognosis should be considered for palliative care with or without WBRT (level 3). It should be recognized, however, that there are limitations in the ability of physicians to accurately predict patient survival. Prognostic systems such as recursive partitioning analysis, and diagnosis-specific graded prognostic assessment may be helpful.

Conclusions: Radiotherapeutic intervention (WBRT or radiosurgery) is associated with improved brain control. In selected patients with single brain metastasis, radiosurgery or surgery has been found to improve survival and locally treated metastasis control (compared with WBRT alone).

Copyright © 2012 American Society for Radiation Oncology. All rights reserved.

References

    1. Mehta MP, Tsao MN, Whelan TJ. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63:37–46.
    1. Tsao MN, Lloyd N, Wong RKS, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases–Full review. Cochrane Database Syst Rev. 2006;3:CD003869.
    1. Tsao MN, Lloyd NS, Wong RK. Clinical practice guideline on the optimal radiotherapeutic management of brain metastases. BMC Cancer. 2005;5:34.
    1. Gaspar LE, Mehta MP, Patchell RA. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence based clinical practice guideline. J Neurooncol. 2010;96:17–32.
    1. Kalkanis SN, Kondziolka D, Gaspar LE. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:33–43.
    1. Mehta MP, Paleologos NA, Mikkelsen T. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:71–83.
    1. Linskey ME, Andrews DW, Asher AL. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:45–68.
    1. Ryken TC, McDermott M, Robinson PD. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:103–114.
    1. Chougule PB, Burton-Williams M, Saris M. Randomized treatment of brain metastases with gamma knife radiosurgery, whole brain radiotherapy or both. Int J Radiat Oncol Biol Phys. 2000;48:114. [Abstract]
    1. Noordijk EM, Vecht CJ, Haaxma-Reiche H. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711–717.
    1. Vecht CJ, Haaxma-Reiche H, Noordijk EM. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583–590.
    1. US Preventative Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Agency for Healthcare Research and Quality (US); Rockville (MD): 1998.
    1. Gaspar LE, Scott C, Rotman M. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–751.
    1. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000;47:1001–1006.
    1. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510–514.
    1. Weltman E, Salvajoli JV, Brandt RA. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys. 2000;46:1155–1161.
    1. Lorenzoni J, Devriendt D, Massager N. Radiosurgery treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004;60:218–224.
    1. Golden DW, Lamborn KR, McDermott MW. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg. 2008;109(Suppl):77–86.
    1. Rades D, Dunst J, Schild SE. A new scoring system to predicting the survival of patients treated with whole brain radiotherapy for brain metastases. Strahlenther Onkol. 2008;184:251–255.
    1. Sperduto PW, Chao ST, Sneed PK. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655–661.
    1. Sperduto PW, Xu Z, Sneed P. The graded prognostic assessment for women with brain metastases from breast cancer (GPA-Breast): a Diagnosis-Specific Prognostic Index. Int J Radiat Oncol Biol Phys. 2010;78(suppl):S6–S7.
    1. Patchell RA, Tibbs PA, Regine WF. Postoperative radiotherapy in the treatment of single metastasis to the brain. JAMA. 1998;280:1485–1489.
    1. Kocher M, Soffietti R, Abacioglu U. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134–141.
    1. Roos DE, Wirth A, Burmeister BH. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05) Radiother Oncol. 2006;80:318–322.
    1. Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg. 1993;79:210–216.
    1. Roberge D, Petrecca K, El Refae M, Souhami L. Whole brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastasis. J Neuro Oncol. 2009;95:95–99.
    1. Soltys SG, Adler JR, Lipani JD. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys. 2008;70:187–193.
    1. Jagannathan J, Yen CP, Ray DK. Gamma knife radiosurgery to the surgical cavity following resection of brain metastases. J Neurosurg. 2009;111:431–438.
    1. Do L, Pezner R, Radany E, Liu A, Staud C, Badie B. Resection followed by stereotactic radiosurgery to resection cavity for intracranial metastases. Int J Radiat Oncol Biol Phys. 2009;73:486–491.
    1. Quigley MR, Fuhrer R, Karlovits S, Karlovits B, Johnson M. Single session stereotactic radiosurgery boost to the post-operative site in lieu of whole brain radiation in metastatic brain disease. J Neurooncol. 2008;87:327–332.
    1. Mathieu D, Knodziolka D, Flickinger JC. Tumor bed radiosurgery after resection of cerebral metastases. Neurosurg. 2008;62:817–823.
    1. Bahl G, White G, Alksne J, Vemuri L, Spear MA. Focal radiation therapy of brain metastases after complete surgical resection. Med Oncol. 2006;23:317–324.
    1. Hwang SW, Abozed MM, Hale A. Adjuvant Gamma Knife radiosurgery following surgical resection of brain metastases: a 9-year retrospective cohort study. J Neurooncol. 2010;98:77–82.
    1. Tolentino PJ. Brain metastases secondary to breast cancer: treatment with surgical resection and stereotactic radiosurgery. Mo Med. 2009;106:428–431.
    1. Karlovits BJ, Quigley MR, Karlovits SM. Stereotactic radiosurgery boost to the resection bed for oligometastatic brain disease: challenging the tradition of adjuvant whole-brain radiotherapy. Neurosurg Focus. 2009;27:E7.
    1. Lindvall P, Bergström P, Löfroth PO, Tommy Bergenheim A. A comparison between surgical resection in combination with WBRT or hypofractionated stereotactic irradiation in the treatment of solitary brain metastases. Acta Neurochir. 2009;151:1053–1059.
    1. Limbrick DD, Jr, Lusis EA, Chicoine MR. Combined surgical resection and stereotactic radiosurgery for treatment of cerebral metastases. Surg Neurol. 2009;71:280–288.
    1. Iwai Y, Yamanaka K, Yasui T. Boost radiosurgery for treatment of brain metastases after surgical resections. Surg Neurol. 2008;69:181–186.
    1. Iwadate Y, Namba H, Yamaura A. Whole brain radiation therapy is not beneficial as adjuvant therapy for brain metastases compared with localized irradiation. Anticancer Res. 2002;22:325–330.
    1. Coucke PA, Zouhair A, Ozsahin M, De Tribolet N, Mirimanoff RO. Focalized external radiotherapy for resected solitary brain metastasis: does the dogma stand? Radiother Oncol. 1998;47:99–101.
    1. Roberge D, Souhami L. Tumor bed radiosurgery following resection of brain metastases: a review. Technol Cancer Res Treat. 2010;9:597–602.
    1. Mintz AH, Kestle J, Rathbone MP. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with single brain metastasis. Cancer. 1996;78:1470–1476.
    1. Patchell RA, Tibbs PA, Walsh JW. A randomized trial of surgery in the treatment of single metastasis to the brain. N Engl J Med. 1990;322:494–500.
    1. Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastasis to brain: a randomized controlled multicentre phase III trial. J Neurooncol. 2008;87:299–307.
    1. Roos DE, Smith JG, Stephens SW. Radiosurgery versus surgery, both with adjuvant whole brain radiotherapy, for solitary brain metastases: a randomized controlled trial. Clin Oncol (R Coll Radiol) 2011;23:646–651.
    1. Schöggl A, Kitz K, Reddy M. Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of single brain metastases. Acta Neurochir (Wien) 2000;142:621–626.
    1. O'Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O'Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys. 2003;55:1169–1176.
    1. Rades D, Kueter JD, Veninga T, Gliemroth J, Schild SE. Whole brain radiotherapy plus stereotactic radiosurgery (WBRT +SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: results of a matched pair analysis. Eur J Cancer. 2009;45:400–404.
    1. Rades D, Kueter JD, Pluemer A, Veninga T, Schild SE. A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one to two brain metastases. Int J Radiat Oncol Biol Phys. 2009;73:1077–1081.
    1. Manon R, O'Neill A, Knisely J. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma and sarcoma: an Eastern Cooperative Oncology Group Study (E 6397) J Clin Oncol. 2005;23:8870–8876.
    1. Andrews DW, Scott CB, Sperduto PW. Whole brain radiation therapy with and without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–1672.
    1. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD. Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys. 2006;64:898–903.
    1. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–434.
    1. Chang EL, Wefel JS, Hess KR. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037–1044.
    1. Serizawa T, Hirai T, Nagano O. Gamma knife radiosurgery for 1-10 brain metastases without prophylactic whole-brain radiation therapy: analysis of cases meeting the Japanese prospective multi-institute study (JLG0901) inclusion criteria. J Neurooncol. 2010;98:163–167.
    1. Aoyama H, Shirato H, Tago M. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483–2491.
    1. Aoyama H, Tago M, Kato N. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68:1388–1395.
    1. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts or sensitivity. [Editorial] J Clin Oncol. 2003;21:3557–3558.
    1. Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med. 1971;111:334–336.
    1. Haie-Meder C, Pellae-Cosset B, Laplanche A. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol. 1993;26:111–116.
    1. Borgelt B, Gelber R, Kramer S. The palliation of brain metastases: final results of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:1–9.
    1. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7:1633–1638.
    1. Chatani M, Teshima T, Hata K, Inoue T, Suzuki T. Whole brain irradiation for metastases from lung carcinoma. A clinical investigation. Acta Radiol Oncol. 1985;24:311–314.
    1. Harwood AR, Simson WJ. Radiation therapy of cerebral metastases: a randomized prospective clinical trial. Int J Radiat Oncol Biol Phys. 1977;2:1091–1094.
    1. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favourable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7:891–895.
    1. Murray KJ, Scott C, Greenberg H. A randomized phase III study of accelerated hyperfracionation versus standard in patients with unresectable brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997;39:571–574.
    1. Priestman TJ, Dunn J, Brada M. Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) 1996;8:308–315.
    1. Davey P, Hoegler D, Ennis M, Smith J. A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol. 2008;88:173–176.
    1. Graham PH, Bucci J, Browne L. Randomized comparison of whole brain radiotherapy, 20 Gy in 4 daily fractions versus 40 Gy in 20 twice-daily fractions for brain metastases. Int J Radiat Oncol Biol Phys. 2010;77:648–654.
    1. Scott C, Suh J, Stea B, Nabid A, Hackman J. Improved survival, quality of life, and quality adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole brain radiation therapy for brain metastases. Am J Clin Oncol. 2007;30:580–587.
    1. Suh JH, Stea B, Tankel K. Results of the phase III ENRICH (RT-016) study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2008;72(Suppl):S50–S51.
    1. DeAngelis LM, Currie VE, Kim JH. The combined use of radiation therapy and lonidamide in the treatment of brain metastases. J Neurooncol. 1989;7:241–247.
    1. Eyre HJ, Ohlsen JD, Frank J. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment of metastatic cancer to brain. J Neurooncol. 1984;2:325–330.
    1. Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG -7916) Int J Radiat Oncol Biol Phys. 1991;20:53–58.
    1. Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ. Results of the randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys. 1995;33:339–348.
    1. Mehta MP, Shapiro WR, Phan SC. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in nonsmall-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys. 2009;73:1069–1076.
    1. Postmus PE, Haaxma-Reiche H, Smit EF. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole brain radiotherapy- a phase III study of the European Organization for the Research and Treatment of Lung Cancer Cooperative Group. J Clin Oncol. 2000;18:3400–3408.
    1. Ushio Y, Arita N, Hayakawa T. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurg. 1991;28:201–205.
    1. Antonadou D, Paraskevaidis M, Saris G. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20:3644–3650.
    1. Mornex F, Thomas L, Mohr P. Randomized phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma. Cancer Radiother. 2003;7:1–8. [Article in French]
    1. Knisely JPS, Berkey B, Chakravarti A. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118) Int J Radiat Oncol Biol Phys. 2008;71:79–86.
    1. Neuhaus T, Ko Y, Muller RP. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer. 2009;100:291–297.
    1. Robinet G, Thomas P, Breton JL. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12:59–67.
    1. Lee DH, Han J-Y, Kim HT. Primary chemotherapy for newly diagnosed NSCLC with synchronous brain metastases compared with WBRT administered first. Result of a randomized pilot study. Cancer. 2008;113:143–149.
    1. Komosinska K, Kepka L, Niwinska A. Prospective evaluation of the palliative effect of whole brain radiotherapy in patients with brain metastases and poor performance status. Acta Oncol. 2010;49:382–388.
    1. Campos S, Davey P, Hird A. Brain metastasis from an unknown primary or primary brain tumour? A diagnostic dilemma. Curr Oncol. 2009;16:62–66.
    1. Cancer Research UK A trial looking at the treatment of lung cancer which has spread to the brain (Quartz) 2011. Available at: Accessed September 19, 2011.
    1. Regine WF, Huhn JL, Patchell RA. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys. 2002;52:333–338.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner